In a groundbreaking Social Media Monitoring initiative, a leading biopharmaceutical company leveraged key performance metrics from LinkedIn and X to collate real-time data on obesity and type-2 diabetes related content.
Let's TalkThe client operated across the obesity and T2D therapeutic landscape, however, only had partial insights on real-time expert interpretation of clinical / scientific data release. This made it difficult to prioritize engagement strategies and messaging that mattered most across the broader HCP community.
Given the limited insights into how HCPs perceived competitors' therapies and approaches on social media, the client could not identify upcoming clinical trends and areas of scientific debate. This led to hindrance in product positioning aspects, such as clinical relevance, patient outcomes and engagement strategies.
The client did not have a structured way to quantify HCP influence, sentiment and engagement risk at the influencer level, or to link these metrics to revenue, pipeline impact and market access.